Hemorrhage is the leading cause of death from combat trauma and the second leading cause of civilian death. Trauma is mainly treated with intravenous liquids, such as isotonic crystalloid solutions. Although volume expansion is desirable, none of these solutions is capable of overcoming tissue oxygen deficits (ischemia). Proper use of transfused blood can assist in resuscitation; however there are significant problems with its use, including storage restraints, availability, typing, risk of disease transmission and immune suppression. These issues make the routine use of stored human blood for use outside the hospital impractical. In an attempt to overcome many of these issues, efforts have been made to develop hemoglobin based oxygen carrier (HBOCs) blood substitutes which have advantages such as decreased chance of disease transmission, lack of a need for typing, and most importantly improved availability with decreased storage demands. Prolong Pharmaceuticals has developed a unique HBOC product for the treatment of severe hemorrhagic shock consisting of a combination of PEGylated bovine hemoglobin (PEG-Hb) and hypertonic saline (HS). It is specifically designed to increase the oxygen carrying capacity of blood as well as to enhance the delivery of oxygen to tissues by keeping the vasculature open through its hypertonic-oncotic actions. We have found this product to be capable of rapidly restoring tissue oxygenation and repaying oxygen debt in an animal model of severe traumatic shock. In this Fast- Track SBIR grant, we will conduct the preclinical studies needed to support an IND to conduct clinical testing of the product. In the phase I component, we will conduct pharmacokinetic analysis of PEG-Hb/HS to define optimal dosing for follow up efficacy and toxicology assessment and to establish dosing parameters for future clinical studies. In the phase II SBIR component we will conduct additional efficacy studies to determine the extent of survival that PEG-Hb/HS induces in our animal model of trauma and will also perform toxicology assessment to support the future use of this product in the treatment of trauma.
Thesaurus Terms: Active Follow-Up; Aliquot; Animal Model; Animal Models And Related Studies; Animals; Applications Grants; Area; Artificial Erythrocytes; Assay; Au Element; Bioassay; Biochemistry; Biologic Assays; Biological Assay; Blood; Blood Plasma; Blood Sample; Blood Substitutes; Blood Transfusion; Blood Erythrocyte; Blood Normocyte; Blood Specimen; Blood, Artificial; Body Tissues; Bolus; Bolus Infusion; Bovine Species; Canine Species; Canis Familiaris; Caring; Carrying Capacities; Cattle; Cause Of Death; Cessation Of Life; Chemistry, Biological; Circulatory Collapse; Clinical; Clinical Evaluation; Clinical Testing; Clinical Trials; Clinical Trials, Phase I; Clinical Trials, Unspecified; Common Rat Strains; Conduct Clinical Trials; Data; Death; Development; Dogs; Dose; Drug Formulations; Drug Kinetics; Drug Or Chemical Tissue Distribution; Drugs; Early-Stage Clinical Trials; Emergencies; Emergency Medicine; Emergency Situation; Engineering; Engineerings; Erythrocyte Substitutes; Erythrocytes; Erythrocytic; Evaluation; Exposure To; Family Suidae; Formulation; Formulations, Drug; Future; Gold; Grant; Grant Proposals; Grants, Applications; Guidelines; Hosp; Half-Life; Half-Lifes; Hemoglobin; Hemorrhagic Shock; Hespan; Hetastarch; Histology; Histopathology; Hospitals; Hour; Human; Human Volunteers; Human, General; Hydroxyethyl Starch; Iv Drip; Immune; Injury; Intravenous Drip; Intravenous Infusion; Ischemia; Isokinetic Exercise; Isokinetics; Isotonic Exercise; Isotonics; Jugular Veins; Knowledge; Life; Liquid Substance; Macrogols; Mammals, Dogs; Mammals, Rats; Man (Taxonomy); Man, Modern; Marrow Erythrocyte; Maximal Tolerated Dose; Maximally Tolerated Dose; Maximum Tolerated Dose; Measures; Medical; Medication; Modeling; Mortality; Mortality Vital Statistics; O Element; O2 Element; Operation; Operative Procedures; Operative Surgical Procedures; Organ; Organ Failure; Oxygen; Peg; Peg-Hb; Peg-Hemoglobin; Patients; Pentastarch; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Preparations; Pharmaceuticals; Pharmacokinetics; Pharmacologic Substance; Pharmacological Substance; Phase; Phase 1 Clinical Trials; Phase I Clinical Trials; Phase I Study; Physiology; Pigs; Plasma; Polyethylene Glycols; Polyethylene Oxide; Polyethyleneoxide; Polyoxyethylenes; Post-Translational Modifications; Post-Translational Protein Processing; Posttranslational Modifications; Pressure; Pressure- Physical Agent; Production; Property; Property, Loinc Axis 2; Protein Modification; Protein Modification, Post-Translational; Protein Processing, Post-Translational; Protein Processing, Posttranslational; Protein/Amino Acid Biochemistry, Post-Translational Modification; Proteins; Protocols, Treatment; Rgm; Rat; Rats, Sprague-Dawley; Rattus; Reaction; Red Blood Cells; Red Cell; Red Cell Substitutes; Red Blood Corpuscule; Red Cell Of Marrow; Regimen; Resuscitation; Reticuloendothelial System, Blood; Reticuloendothelial System, Erythrocytes; Reticuloendothelial System, Serum, Plasma; Risk; Sbir; Sbirs (R43/44); Safety; Saline; Saline Solution; Sampling; Serum, Plasma; Shock; Shock, Hemorrhagic; Shock, Traumatic; Small Business Innovation Research; Small Business Innovation Research Grant; Solutions; Specialist; Spectroscopy; Spectrum Analyses; Spectrum Analysis; Sprague-Dawley Rats; Staging; Starch, 2-Hydroxyethyl Ether; Structure Of Jugular Vein; Suidae; Surgical; Surgical Interventions; Surgical Procedure; Swine; Technology; Testing; Therapeutic; Time; Tissue Distribution; Tissues; Toxic Effect; Toxicities; Toxicokinetics; Toxicology; Trauma; Traumatic Shock; Treatment Protocols; Treatment Regimen; Treatment Schedule; United States; Universities; Virginia; Volunteers, Human; Whblood; Whole Blood; Base; Blood Corpuscles; Bovid; Bovine; Canine; Circulatory Shock; Clinical Investigation; Clinical Test; Combat; Communicable Disease Transmission; Cost; Cow; Data Modeling; Design; Designing; Disease Transmission; Domestic Dog; Drip Infusion; Drug Detection; Drug Testing; Drug/Agent; Effective Therapy; Efficacy Testing; Fluid; Follow-Up; Gene Product; Hemodynamics; Improved; In Vivo; Infectious Disease Transmission; Injured; Intravenous Administration; Liquid; Model Organism; Novel; Oxygen Debt; Oxygen Transport; Phase 1 Study; Phase 1 Trial; Phase I Trial; Point Of Care; Polyethylene Glycol-Hemoglobin Conjugate; Porcine; Pre-Clinical; Preclinical; Preclinical Efficacy; Preclinical Study; Pressure; Product Development; Professor; Protocol, Phase I; Public Health Relevance; Research Clinical Testing; Safety Testing; Sample Collection; Specimen Collection; Standard Care; Stem; Suid; Surgery; Time Interval; Tissue Oxygen Saturation; Tissue Oxygenation; Vein Infusion; Ward
